CNTB vs. CRVS, JAGX, HOOK, MRNS, LFVN, BTAI, TPST, VACC, AFMD, and BRNS
Should you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include Corvus Pharmaceuticals (CRVS), Jaguar Health (JAGX), Hookipa Pharma (HOOK), Marinus Pharmaceuticals (MRNS), LifeVantage (LFVN), BioXcel Therapeutics (BTAI), Tempest Therapeutics (TPST), Vaccitech (VACC), Affimed (AFMD), and Barinthus Biotherapeutics (BRNS). These companies are all part of the "pharmaceutical preparations" industry.
Corvus Pharmaceuticals (NASDAQ:CRVS) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.
46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 31.3% of Corvus Pharmaceuticals shares are held by insiders. Comparatively, 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Corvus Pharmaceuticals received 270 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 69.57% of users gave Connect Biopharma an outperform vote while only 62.31% of users gave Corvus Pharmaceuticals an outperform vote.
Corvus Pharmaceuticals' return on equity of 0.00% beat Connect Biopharma's return on equity.
Corvus Pharmaceuticals currently has a consensus price target of $6.88, suggesting a potential upside of 213.93%. Connect Biopharma has a consensus price target of $6.50, suggesting a potential upside of 270.37%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Connect Biopharma is more favorable than Corvus Pharmaceuticals.
In the previous week, Corvus Pharmaceuticals had 1 more articles in the media than Connect Biopharma. MarketBeat recorded 4 mentions for Corvus Pharmaceuticals and 3 mentions for Connect Biopharma. Corvus Pharmaceuticals' average media sentiment score of 1.59 beat Connect Biopharma's score of 1.01 indicating that Connect Biopharma is being referred to more favorably in the news media.
Corvus Pharmaceuticals has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.49, indicating that its stock price is 149% less volatile than the S&P 500.
Summary
Connect Biopharma beats Corvus Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
Get Connect Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Connect Biopharma Competitors List
Related Companies and Tools
